Elucidating cell signaling mechanisms using antisense technology

Trends in Pharmacological Sciences

Volumn 21, Issue 4, 2000, Pages 142-148

  Koller, Erich ^a   Gaarde, William A ^a   Monia, Brett P ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; FOMIVIRSEN; GENE EXPRESSION MODULATOR 132; ISIS 3521; OBLIMERSEN;

DRUG DEVELOPMENT; GENE OVEREXPRESSION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; SIGNAL TRANSDUCTION;

EID: 0034176085     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01448-6     Document Type: Review

References (40)

1. Yin, M.J. et al. (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-β. Nature 396, 77-80
2. Crooke, S.T. (1999) Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489, 31-44
3. Baker, B.F. and Monia, B.P. (1999) Novel mechanisms for antisense-mediated regulation of gene expression. Biochim. Biophys. Acta 1489, 3-18
4. Monia, B.P. et al. Antisense approaches for the treatment of cancer. Cancer Invest, (in press)
5. Glennon, P.E. et al. (1996) Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ. Res. 78, 954-961
6. Potapova, O. et al. Inhibition of JNK2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol. Cell. Biol. (in press)
7. Bost, F. et al. (1999) The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell. Biol. 19, 1938-1949
8. Oliff, A. (1999) Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta 1423, C19-C30
9. Borsch-Haubold, A.G. et al. (1998) Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J. Biol. Chem. 273, 28766-28772
10. Ashkenazi, A. and Dixit, V.M. (1998) Death receptors: signaling and modulation. Science 281, 1305-1308
11. Crooke, S.T. and Bennett, C.F. (1996) Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 107-129
12. Monia, B.P. and Dean, N.M. (1997) Pharmacological activity of antisense oligonucleotides in animal models of disease. In Antisense Research and Application (Vol. 131) (Crooke, S.T., ed.), pp. 427-443, Springer-Verlag
13. Orr, R.M. and Monia, B.P. (1998) Antisense therapy for cancer. Invest. Drugs 1, 199-205
14. Perry, C.M. and Balfour, J.A. (1999) Fomivirsen. Drugs 57, 375-380
15. Levin, A.A. (1999) A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84
16. Stein, C.A. (1999) Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochim. Biophys. Acta 1489, 45-52
17. Altmann, K-H. et al. (1996) Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia 50, 168-176
18. Freier, S.M. and Altmann, K.H. (1997) The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429-4443
19. Flanagan, W.M. et al. (1999) Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide. Nat. Biotechnol. 17, 48-52
20. Flanagan, W.M. et al. (1999) A novel cytosine analog that confers enhanced potency to antisense oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 96, 3513-3518
21. Bennett, C.F. (1998) Use of cationic lipid complexes for antisense oligonucleotide delivery. In Applied Antisense Oligonucleotide Technology (Stein, C.A. and Krieg, A.M., eds), pp. 129-145, Wiley-Liss
22. Griffey, R.H. et al. (1996) 2′-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. J. Med. Chem. 39, 5100-5109
23. Bost, F. et al. (1997) The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells J. Biol. Chem. 272, 33422-33429
24. Bennett, C.F. et al. (1995) Pharmacology of antisense therapeutic agents. In Methods in Molecular Medicine: Antisense Therapeutics (Agrawal, S., ed.), pp. 13-46, Humana Press
25. Chen, G. et al. (1996) Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem. 271, 28259-28265
26. Robinson, C.J. et al. (1996) Treatment of vascular smooth muscle cells with antisense phosphorothioate oligodeoxynucleotides directed against p42 and p44 mitogen-activated protein kinases abolishes DNA synthesis in response to platelet-derived growth factor. Biochem. J. 320, 123-127
27. 2-terminal kinase-mediated activation of interleukin-1β converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J. Biol. Chem. 272, 4631-4636
28. Cioffi, C.L. and Monia, B.P. (2000) Evaluation of biological role of c-Jun N-terminal kinase using an antisense approach. Methods Enzymol. 314, 363-378
29. Cioffi, C.L. et al. (1997) Selective inhibition of A-Rafand C-RafmRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Rafand C-Raf in serum-induced proliferation. Mol. Pharmacol. 51, 383-389
30. Duff, J.L. et al. (1995) Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells. Effect of actinomycin D and antisense oligonucleotides. J. Biol. Chem. 270, 7161-7166
31. Siddhanta, U. et al. (1998) Distinct roles for the p110α and hVPS34 phosphatidylinositol 3′-kinases in vesicular trafficking, regulation of the actin cytoskeleton, and mitogenesis. J. Cell. Biol. 143, 1647-1659
32. 2-terminal kinases, in human epithelial cells, by two independent pathways. Biochem. Biophys. Res. Commun. 251, 166-172
33. Roy, B. and Cathcart, M.K. (1998) Induction of 15-lipoxygenase expression by IL-13 requires tyrosine phosphorylation of Jak2 and Tyk2 in human monocytes. J. Biol. Chem. 273, 32023-32029
34. i2 protein a subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells. Mol. Pharmacol. 48, 189-193
35. i3. Biochem. J. 303, 369-375
36. Ziegler, A. et al. (1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst. 89, 1027-1036
37. Ackermann, E.J. et al. (1999) The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J. Biol. Chem. 274, 11245-11252
38. Zuo, Z. et al. (1998) Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest. J. Biol. Chem. 273, 12250-12258
39. Chen, L.Z. et al (1998) Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-β1. Proc. Natl Acad. Sci. U. S. A. 95, 12516-12521
40. Li, F. et al. (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1, 461-466